NASDAQ · ADAG
Healthcare · Biotechnology
$3.58
Down-$0.06 (-1.68%)
Updated Sep 8, 2026, 7:02 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ADAG closed at $3.58 after 20 trading sessions, down 12.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $3.67 | $3.6921 | $3.56 | $3.58 | 28.19K |
| Sep 3, 2026 | $3.71 | $3.85 | $3.56 | $3.69 | 167.71K |
| Sep 2, 2026 | $3.60 | $3.74 | $3.5999 | $3.69 | 102.67K |
| Sep 1, 2026 | $3.51 | $3.675 | $3.42 | $3.64 | 120.55K |
| Aug 31, 2026 | $3.62 | $3.62 | $3.4512 | $3.51 | 131.62K |
| Aug 28, 2026 | $3.89 | $3.89 | $3.66 | $3.68 | 123.15K |
| Aug 27, 2026 | $3.85 | $3.97 | $3.71 | $3.90 | 296.25K |
| Aug 26, 2026 | $3.97 | $4.09 | $3.82 | $3.85 | 122.15K |
| Aug 25, 2026 | $3.90 | $3.97 | $3.80 | $3.82 | 63.07K |
| Aug 24, 2026 | $3.99 | $4.005 | $3.795 | $3.90 | 159.18K |
| Aug 21, 2026 | $4.11 | $4.115 | $3.97 | $4.02 | 61.31K |
| Aug 20, 2026 | $4.11 | $4.18 | $4.01 | $4.09 | 205.03K |
| Aug 19, 2026 | $4.11 | $4.1904 | $4.00 | $4.12 | 278.43K |
| Aug 18, 2026 | $3.81 | $4.19 | $3.78 | $4.05 | 332.57K |
| Aug 17, 2026 | $3.63 | $3.99 | $3.59 | $3.83 | 1.05M |
| Aug 14, 2026 | $3.75 | $3.825 | $3.58 | $3.70 | 152.28K |
| Aug 13, 2026 | $3.77 | $3.91 | $3.652 | $3.72 | 123.29K |
| Aug 12, 2026 | $4.04 | $4.2392 | $3.71 | $3.75 | 294.44K |
| Aug 11, 2026 | $4.07 | $4.075 | $3.85 | $3.89 | 276.4K |
| Aug 10, 2026 | $4.11 | $4.17 | $3.95 | $4.07 | 566.48K |
The latest Smart Investors Daily articles mentioning ADAG.
ADAG research
Company profile and research snapshot.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 6, 2026 | Guggenheim | Buy | — |
| Nov 24, 2025 | Guggenheim | Buy | — |
| Sep 18, 2025 | LUCID CAPITAL MARKETS | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2025 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.10) by 100 percent. This is a 5.26 percent decrease over losses of $(0.19) per share from the same
Yahoo · Nov 13, 2025
SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor associated antigens. Under the terms of the agreement, Third Arc Bio will receive rights to research, develop and commercialize two candidate molecules worl
GlobeNewswire Inc. · Nov 13, 2025
Adagene has signed a licensing agreement with Third Arc Bio to utilize its SAFEbody technology platform for developing two masked CD3 T cell engagers targeting unique tumor-associated antigens. The deal includes an upfront payment of $5 million and potential milestone payments up to $840 million.
zacks.com · Sep 30, 2025
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ADAG.
